CONTER, VALENTINO
CONTER, VALENTINO
Autologous Purified Peripheral Blood Stem Cell Transplantation Compare to Chemotherapy in Childhood Acute Lymphoblastic Leukemia after Low-Risk Relapse
2011 Balduzzi, A; Galimberti, S; Valsecchi, M; Bonanomi, S; Conter, V; Barth, A; Rovelli, A; Henze, G; Biondi, A; von Stackelberg, A
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
2014 Balduzzi, A; DI MAIO, L; Silvestri, D; Songia, S; Bonanomi, S; Rovelli, A; Conter, V; Biondi, A; Cazzaniga, G; Valsecchi, M
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia
2014 Paganin, M; Fabbri, G; Conter, V; Barisone, E; Polato, K; Cazzaniga, G; Giraldi, E; Fagioli, F; Aricò, M; Valsecchi, M; Basso, G
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000
2016 Möricke, A; Zimmermann, M; Valsecchi, M; Stanulla, M; Biondi, A; Mann, G; Locatelli, F; Cazzaniga, G; Niggli, F; Aricò, M; Bartram, C; Attarbaschi, A; Silvestri, D; Beier, R; Basso, G; Ratei, R; Kulozik, A; Lo Nigro, L; Kremens, B; Greiner, J; Parasole, R; Harbott, J; Caruso, R; von Stackelberg, A; Barisone, E; Rössig, C; Conter, V; Schrappe, M
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis
2016 Conter, V; Valsecchi, M; Buldini, B; Parasole, R; Locatelli, F; Colombini, A; Rizzari, C; Putti, M; Barisone, E; Nigro, L; Santoro, N; Ziino, O; Pession, A; Testi, A; Micalizzi, C; Casale, F; Pierani, P; Cesaro, S; Cellini, M; Silvestri, D; Cazzaniga, G; Biondi, A; Basso, G
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia
2016 Palmi, C; Savino, A; Silvestri, D; Bronzini, I; Cario, G; Paganin, M; Buldini, B; Galbiati, M; Muckenthaler, M; Bugarin, C; Mina, P; Nagel, S; Barisone, E; Casale, F; Locatelli, F; Nigro, L; Micalizzi, C; Parasole, R; Pession, A; Putti, M; Santoro, N; Testi, A; Ziino, O; Kulozik, A; Zimmermann, M; Schrappe, M; Villa, A; Gaipa, G; Basso, G; Biondi, A; Valsecchi, M; Stanulla, M; Conter, V; Kronnie, G; Cazzaniga, G
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study
2016 Boer, J; Van Der Veer, A; Rizopoulos, D; Fiocco, M; Sonneveld, E; De Groot Kruseman, H; Kuiper, R; Hoogerbrugge, P; Horstmann, M; Zaliova, M; Palmi, C; Trka, J; Fronkova, E; Emerenciano, M; Do Socorro Pombo De Oliveira, M; Mlynarski, W; Szczepanski, T; Nebral, K; Attarbaschi, A; Venn, N; Sutton, R; Schwab, C; Enshaei, A; Vora, A; Stanulla, M; Schrappe, M; Cazzaniga, G; Conter, V; Zimmermann, M; Moorman, A; Pieters, R; Den Boer, M
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results
2017 Antillón, F; BLANCO LOPEZ, J; Valverde, P; Castellanos, M; Garrido, C; Girón, V; Letona, T; Osorio, E; Borrayo, D; Mack, R; Melgar, M; Lorenzana, R; Ribeiro, R; Metzger, M; Conter, V; Rossi, E; Valsecchi, M
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL
2017 Serafin, V; Lissandron, V; Buldini, B; Bresolin, S; Paganin, M; Grillo, F; Andriano, N; Palmi, C; Cazzaniga, G; Marmiroli, S; Conter, V; Basso, G; Accordi, B
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations
2017 Ballerini, A; Moro, F; Nerini, I; Marzo, C; Di Clemente, A; Ferrari, M; D'Incalci, M; Biondi, A; Colombini, A; Conter, V; Porcu, L; Cervo, L; Rizzari, C; Zucchetti, M
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
2018 Cazzaniga, G; De Lorenzo, P; Alten, J; Röttgers, S; Hancock, J; Saha, V; Castor, A; Madsen, H; Gandemer, V; Cavé, H; Leoni, V; Köhler, R; Ferrari, G; Bleckmann, K; Pieters, R; Van Der Velden, V; Stary, J; Zuna, J; Escherich, G; Stadt, U; Aricò, M; Conter, V; Schrappe, M; Valsecchi, M; Biondi, A
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols
2018 Paganin, M; Grillo, M; Silvestri, D; Scapinello, G; Buldini, B; Cazzaniga, G; Biondi, A; Valsecchi, M; Conter, V; Te Kronnie, G; Basso, G
Oral nutritional supplementation in children treated for cancer in low- and middle-income countries is feasible and effective: The experience of the children's hospital manuel de jesus rivera "la mascota" in Nicaragua
2018 Peccatori, N; Ortiz, R; Rossi, E; Calderon, P; Conter, V; García, Y; Biondi, A; Espinoza, D; Ceppi, F; Mendieta, L; Melzi, M
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial
2018 Biondi, A; Gandemer, V; De Lorenzo, P; Cario, G; Campbell, M; Castor, A; Pieters, R; Baruchel, A; Vora, A; Leoni, V; Stary, J; Escherich, G; Li, C; Cazzaniga, G; Cavé, H; Bradtke, J; Conter, V; Saha, V; Schrappe, M; Grazia Valsecchi, M
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000)
2018 Schrappe, M; Bleckmann, K; Zimmermann, M; Biondi, A; Möricke, A; Locatelli, F; Cario, G; Rizzari, C; Attarbaschi, A; Valsecchi, M; Bartram, C; Barisone, E; Niggli, F; Niemeyer, C; Testi, A; Mann, G; Ziino, O; Schäfer, B; Panzer-Grümayer, R; Beier, R; Parasole, R; Göhring, G; Ludwig, W; Casale, F; Schlegel, P; Basso, G; Conter, V
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
2018 Galimberti, S; Devidas, M; Lucenti, A; Cazzaniga, G; Möricke, A; Bartram, C; Mann, G; Carroll, W; Winick, N; Borowitz, M; Wood, B; Basso, G; Conter, V; Zimmermann, M; Suciu, S; Biondi, A; Schrappe, M; Hunger, S; Valsecchi, M
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: High white blood cell count at diagnosis is the strongest prognostic factor
2019 Biondi, A; Cario, G; De Lorenzo, P; Castor, A; Conter, V; Leoni, V; Gandemer, V; Pieters, R; Stary, J; Escherich, G; Campbell, M; Attarbaschi, A; Li, C; Vora, A; Bradtke, J; Saha, V; Valsecchi, M; Schrappe, M
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study
2019 Testi, A; Attarbaschi, A; Valsecchi, M; Moricke, A; Cario, G; Niggli, F; Silvestri, D; Bader, P; Kuhlen, M; Parasole, R; Putti, M; Lang, P; Flotho, C; Mann, G; Rizzari, C; Barisone, E; Locatelli, F; Linderkamp, C; Lauten, M; Suttorp, M; Zimmermann, M; Basso, G; Biondi, A; Conter, V; Schrappe, M
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study
2019 Crisafulli, S; Sultana, J; Ingrasciotta, Y; Addis, A; Cananzi, P; Cavagna, L; Conter, V; D'Angelo, G; Ferrajolo, C; Mantovani, L; Pastorello, M; Scondotto, S; Trifiro, G
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial
2020 Attarbaschi, A; Mann, G; Zimmermann, M; Bader, P; Barisone, E; Basso, G; Biondi, A; Cario, G; Cazzaniga, G; Colombini, A; Flotho, C; Kuhlen, M; Lang, P; Lauten, M; Linderkamp, C; Locatelli, F; Lo Nigro, L; Moricke, A; Niggli, F; Panzer-Grumayer, R; Parasole, R; Peters, C; Caterina Putti, M; Rizzari, C; Suttorp, M; Valsecchi, M; Conter, V; Schrappe, M